Truqap is often a kinase inhibitor that works by blocking pathways that aid the cancer cells survive and increase, so reduces cancer growth. Truqap is from a category of medicines referred to as an AKT inhibitor. Truqap been given FDA acceptance on November 17, 2023, just after positive benefits with https://rapamycin58023.blog-ezine.com/34933168/top-guidelines-of-pentiapine